GlaxoSmithKline annual profit rises 36%; warns of earnings decline in 2019

Writer, Stock Market Wire
Wednesday, February 6, 2019 - 13:12

GlaxoSmithKline posted a 36% rise in pre-tax profit, underpinned higher sales of its shingles vaccine and respiratory disease treatments, but warned of lower earnings in 2019.

Pre-tax profit for the year through December rose to £4.80bn, as sales climbed 2% to £30.82bn, or by 5% on a constant currency basis.

Adjusted earnings per share rose 7% to 119.4p, or by 12% on a constant currency basis, assisted by improved operating margin and continued financial efficiencies, the company said.

For 2019, GlaxoSmithKline forecast EPS to decline by 5-9% in constant currency, reflecting recent approval of a generic competitor to respiratory disease treatment Advair in the US.

The guidance also reflected the expected impact of the recent Tesaro acquisition and assumed the consumer healthcare disposal and JV with Pfizer was completed to plan.

In 2018, shingles vaccine sales more than doubled to £784m, while total new respiratory product sales rose 35% to £2.6bn.

GlaxoSmithKline declared a full-year dividend of 80p a share, which it forecast to remain flat in 2019.

'GSK delivered improved operating performance in 2018 with group sales growth, strong commercial execution of new product launches, especially Shingrix, continued cost discipline and better cash generation,' chief executive Emma Walmsley said.

At 1:12pm: (LON:GSK) GlaxoSmithKline PLC share price was +10.8p at 1533.4p

Related content

Kingfisher in a fix as DIY expert looks for a new boss

Kingfisher’s failure to increase its dividend for a tenth year in a row – and join an elite club of just 26 current FTSE...

Wed, 20/03/2019 - 15:47

Broker Forecast - Shore Capital issues a broker note on GlaxoSmithKline PLC

Shore Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to hold (from buy).

Broker Forecasts data provided by

Fri, 08/03/2019 - 08:50

GlaxoSmithKline's JV ViiV Healthcare says trials for injectable HIV treatment met objectives

GlaxoSmithKline said Friday its ViiV Healthcare joint venture with Pfizer had said two clinical trials of a an injectable two-drug regime for the treatment of...

Fri, 08/03/2019 - 07:31

How I invest: hoping for good returns in retirement

Peter from Bromley has been investing in the stock market since the 1980s when he bought shares in British Gas. Now aged 71, the former...

Thu, 07/03/2019 - 00:00

UK drops fraud investigation in GlaxoSmithKline, Rolls-Royce

Britain's Serious Fraud Office said it had dropped investigations into individuals at GlaxoSmithKline and Rolls-Royce.

'After an extensive and careful examination I have concluded that...

Fri, 22/02/2019 - 13:08